Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Net Margin readings, the most recent being 29.49% for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 9426.0% year-over-year to 29.49%, compared with a TTM value of 2.23% through Dec 2025, up 528.0%, and an annual FY2025 reading of 2.23%, up 528.0% over the prior year.
  • Net Margin hit 29.49% in Q4 2025 for Apellis Pharmaceuticals, down from 47.04% in the prior quarter.
  • The five-year high for Net Margin was 470.05% in Q4 2021, with the low at 35183.15% in Q2 2021.
  • Median Net Margin over the past 5 years was 55.29% (2025), compared with a mean of 2215.42%.
  • The largest YoY upside for Net Margin was 3422752bps in 2022 against a maximum downside of -83707bps in 2022.
  • Year by year, Net Margin stood at 470.05% in 2021, then tumbled by -178bps to 367.01% in 2022, then surged by 93bps to 27.39% in 2023, then skyrocketed by 337bps to 64.77% in 2024, then plummeted by -146bps to 29.49% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 29.49%, 47.04%, and 23.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.